8-K
filed January 23, 2026, 6:59 PM ET
ticker RVPH
CIK 0001742927
other material
confidence high
sentiment neutral
materiality 0.65
Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance
REVIVA PHARMACEUTICALS HOLDINGS, INC.
- Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.
- Company requested hearing after delisting determination on Nov 11, 2025; hearing held Jan 8, 2026.
- To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
- Company may implement reverse stock split if needed; warns split may not maintain price increase.
- Risk of delisting remains if unable to meet deadline or other Nasdaq listing requirements.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001437749-26-001913
- form_type
- 8-K
- ticker
- RVPH
- cik
- 0001742927
- company_name
- REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at
- 2026-01-23T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:36.052134+00:00
- generated_at
- 2026-05-16T08:27:45.436816+00:00
- sec_items
- ["3.01", "8.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001437749-26-001913
- json_url
- https://secwatch.observer/filing/0001437749-26-001913.json
- markdown_url
- https://secwatch.observer/filing/0001437749-26-001913.md
- text_url
- https://secwatch.observer/filing/0001437749-26-001913.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/rvph20260122_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ISPC
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
iSpecimen Inc.
May 13, 2026, 5:00 PM ET
other_material
Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026
Filing page
SEC filing
GNLN
Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027
Greenlane Holdings, Inc.
April 27, 2026, 7:59 PM ET
other_material
Items 3.01, 7.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice
(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)
indicating that Nasdaq s
Filing page
SEC filing
TNON
Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity
Tenon Medical, Inc.
May 22, 2026, 5:15 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
May 21, 2026, Tenon Medical, Inc. (the “Company”)
received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying
the Company that it is no longer in compliance with the
Filing page
SEC filing
AGAE
AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K
Allied Gaming & Entertainment Inc.
May 21, 2026, 9:40 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
May 19, 2026, All In FutureTech Alliance,
Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)
from the Listing Qualifications Department (the “Staff”) of
Filing page
SEC filing
SNYR
Synergy CHC receives Nasdaq delisting notice for bid price below $1.00
Synergy CHC Corp.
May 18, 2026, 9:01 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of
The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing
Filing page
SEC filing
HUMA
Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply
Humacyte, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
May 4, 2026, Humacyte, Inc. (the “Company”)
received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification
that, for the 30 consecutive business days ended May 1, 2026, th
Filing page
SEC filing
XXI
Tether International acquires SoftBank's stake in Twenty One Capital; board members resign
Twenty One Capital, Inc.
May 20, 2026, 8:49 AM ET
other_material
Items 1.02, 3.01, 5.02, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
o independent directors, the minimum number required during the transition period
for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual
Filing page
SEC filing
RVPH
Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB
REVIVA PHARMACEUTICALS HOLDINGS, INC.
May 13, 2026, 8:03 AM ET
other_material
Items 3.01, 8.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 8.01
same event type: other_material
This filing
January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
Comparable filing
May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.